Clinical trials: Erythema
Erythema Migrans, Post-Lyme Disease Symptoms
Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
Background: While doxycycline is a standard antibiotic for treatment of erythema migrans in Europe as well as in the USA, the effectiveness of cefuroxime axetil in the treatment of adult patients with erythema migrans has been…
- Trial name
- NCT01518192
- Testing
- doxycycline, cefuroxime axetil
- Where
- 2 sites in Slovenia
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Hyperemia
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants.
- Trial name
- NCT01959243
- Testing
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein
- Where
- 4 sites in United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Erythema Chronicum Migrans
Duration of Antibiotic Treatment of Erythema Migrans
The purpose of this study is to compare the efficacy of 15-day versus 10-day doxycycline treatment in patients with erythema migrans.
- Trial name
- NCT00910715
- Testing
- doxycycline
- Where
- Slovenia
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc